Page 2 - Sam Gandy News Today

Ralph Carmona participated in a clinical research trial for Leqembi, a new Alzheimer's drug that he believes stopped his symptoms from progressing.

Https://www.youtube.com/watch?v=FqPEUIR5J3k As one old saw goes, in the 60s, we thought computers would enslave us, and drugs would set us free.Jury still out on computers, but clearly the drug thing did not work out as hoped.Obviously psychedelics have had a major impact on every corner of the culture, and I don't think there's any doubt…

Its hard to imagine a more appropriate setting for Amanda Joy Ravenhills first psychedelic experience than Burning Man, the Nevada desert festival that is to fans of hallucinogens what a

A decrease of ca. 1 million Americans with dementia may be due to better control of cardiovascular risk factors like high blood pressure and diabetes.

The medicine, developed by Eisai and Cambridge-based Biogen, is expected to be covered by Medicare.

WEDNESDAY, May 10, 2023 (HealthDay News) -- Researchers have isolated for the first time a free-floating form of amyloid beta that appears to be a key driver of Alzheimer’s disease.

The drug is made by Japan's Eisai and its U.S. partner, Biogen, which is based in Cambridge. Read more at Boston.com.

A new Alzheimer’s drug is hitting the market — the first with clear-cut evidence that it can slow, by several months, the mind-robbing disease. It’s a

Leqembi can slow early progression by months but has safety concerns. Most patients will likely have to wait months to get the IV drug, which will cost about $26,500 a year. Insurers need to decide whether and how much to cover it. Medicare isn’t expected to pay for it until later this year.

United States health officials last week approved a new Alzheimer’s drug. The drug, called Leqembi, is the first to slow the decline in memory by several months.